168 related articles for article (PubMed ID: 28590068)
1. Comparison of HIV-1 drug-resistance genotyping by ultra-deep sequencing and sanger sequencing using clinical samples.
Trabaud MA; Icard V; Ramière C; Tardy JC; Scholtes C; André P
J Med Virol; 2017 Nov; 89(11):1912-1919. PubMed ID: 28590068
[TBL] [Abstract][Full Text] [Related]
2. Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failure.
Mohamed S; Penaranda G; Gonzalez D; Camus C; Khiri H; Boulmé R; Sayada C; Philibert P; Olive D; Halfon P
AIDS; 2014 Jun; 28(9):1315-24. PubMed ID: 24698843
[TBL] [Abstract][Full Text] [Related]
3. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia.
Rodriguez C; Nere ML; Demontant V; Charreau I; Mercier-Darty M; Delagreverie H; Salmona M; de Castro N; Chaix ML; Molina JM; Delaugerre C
J Antimicrob Chemother; 2018 Nov; 73(11):3122-3128. PubMed ID: 30137335
[TBL] [Abstract][Full Text] [Related]
4. Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
Hauser A; Kuecherer C; Kunz A; Dabrowski PW; Radonić A; Nitsche A; Theuring S; Bannert N; Sewangi J; Mbezi P; Dugange F; Harms G; Meixenberger K
PLoS One; 2015; 10(10):e0140809. PubMed ID: 26469189
[TBL] [Abstract][Full Text] [Related]
5. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing.
Simen BB; Braverman MS; Abbate I; Aerssens J; Bidet Y; Bouchez O; Gabriel C; Izopet J; Kessler HH; Stelzl E; Di Giallonardo F; Schlapbach R; Radonic A; Paredes R; Recordon-Pinson P; Sakwa J; St John EP; Schmitz-Agheguian GG; Metzner KJ; Däumer MP;
J Virol Methods; 2014 Aug; 204():31-7. PubMed ID: 24731928
[TBL] [Abstract][Full Text] [Related]
6. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients.
Alidjinou EK; Deldalle J; Hallaert C; Robineau O; Ajana F; Choisy P; Hober D; Bocket L
J Antimicrob Chemother; 2017 Oct; 72(10):2823-2830. PubMed ID: 29091197
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus type 1 drug resistance testing: Evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyping Kit.
Stelzl E; Pröll J; Bizon B; Niklas N; Danzer M; Hackl C; Stabentheiner S; Gabriel C; Kessler HH
J Virol Methods; 2011 Dec; 178(1-2):94-7. PubMed ID: 21907239
[TBL] [Abstract][Full Text] [Related]
8. Shall I trust the report? Variable performance of Sanger sequencing revealed by deep sequencing on HIV drug resistance mutation detection.
Chen NY; Kao SW; Liu ZH; Wu TS; Tsai CL; Lin HH; Wong WW; Chang YY; Chen SS; Ku SW
Int J Infect Dis; 2020 Apr; 93():182-191. PubMed ID: 32061862
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Roche prototype 454 HIV-1 ultradeep sequencing drug resistance assay in a routine diagnostic laboratory.
Garcia-Diaz A; Guerrero-Ramos A; McCormick AL; Macartney M; Conibear T; Johnson MA; Haque T; Webster DP
J Clin Virol; 2013 Oct; 58(2):468-73. PubMed ID: 23954217
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 resistance genotyping by ultra-deep sequencing and 6-month virological response to first-line treatment.
Raymond S; Jeanne N; Nicot F; Dimeglio C; Carcenac R; Harter A; Ranger N; Martin-Blondel G; Delobel P; Izopet J
J Antimicrob Chemother; 2023 Feb; 78(2):346-353. PubMed ID: 36449383
[TBL] [Abstract][Full Text] [Related]
11. Detection of pretreatment minority HIV-1 reverse transcriptase inhibitor-resistant variants by ultra-deep sequencing has a limited impact on virological outcomes.
Su B; Zheng X; Liu Y; Liu L; Xin R; Lu H; Huang C; Bai L; Mammano F; Zhang T; Wu H; Sun L; Dai L
J Antimicrob Chemother; 2019 May; 74(5):1408-1416. PubMed ID: 30668734
[TBL] [Abstract][Full Text] [Related]
12. MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing.
Huber M; Metzner KJ; Geissberger FD; Shah C; Leemann C; Klimkait T; Böni J; Trkola A; Zagordi O
J Virol Methods; 2017 Feb; 240():7-13. PubMed ID: 27867045
[TBL] [Abstract][Full Text] [Related]
13. [The use of ultra deep sequencing technique in the screening program on HIV-1 drug resistance mutation among ART-naїve patients in Hunan province].
He J; Zou X; Chen X; Zheng J
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Oct; 35(10):1142-5. PubMed ID: 25567022
[TBL] [Abstract][Full Text] [Related]
14. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.
Bellecave P; Recordon-Pinson P; Fleury H
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):85-92. PubMed ID: 26529549
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levels.
Kozal MJ; Chiarella J; St John EP; Moreno EA; Simen BB; Arnold TE; Lataillade M
Antivir Ther; 2011; 16(6):925-9. PubMed ID: 21900725
[TBL] [Abstract][Full Text] [Related]
17. Improved detection of resistance at failure to a tenofovir, emtricitabine and efavirenz regimen by ultradeep sequencing.
Todesco E; Rodriguez C; Morand-Joubert L; Mercier-Darty M; Desire N; Wirden M; Girard PM; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2015 May; 70(5):1503-6. PubMed ID: 25614045
[TBL] [Abstract][Full Text] [Related]
18. Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance.
Raymond S; Nicot F; Abravanel F; Minier L; Carcenac R; Lefebvre C; Harter A; Martin-Blondel G; Delobel P; Izopet J
J Clin Virol; 2020 Jan; 122():104229. PubMed ID: 31809945
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and clinical impact of minority resistant variants in patients failing an integrase inhibitor-based regimen by ultra-deep sequencing.
Nguyen T; Fofana DB; Lê MP; Charpentier C; Peytavin G; Wirden M; Lambert-Niclot S; Desire N; Grude M; Morand-Joubert L; Flandre P; Katlama C; Descamps D; Calvez V; Todesco E; Marcelin AG
J Antimicrob Chemother; 2018 Sep; 73(9):2485-2492. PubMed ID: 29873733
[TBL] [Abstract][Full Text] [Related]
20. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
